Monitoring the efficacy of conservative treatment of nasopharyngeal carcinoma by examining Epstein–Barr virus DNA titers in blood plasma (review)
Open Access
- 16 November 2020
- journal article
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 10 (3), 81-89
- https://doi.org/10.17650/2222-1468-2020-10-3-81-89
Abstract
One of the main problems of nasopharyngeal carcinoma treatment is the high incidence regional and distant failures. The method of choice in the first line therapy for the primarily diagnosed nasopharyngeal carcinoma is chemoradiotherapy with poor success rate. The main etiological factor in the occurrence of nasopharyngeal carcinoma is the Epstein–Barr virus, which DNA’s copies could be detected in blood samples in patients with nasopharyngeal carcinoma, which may indicate tumor activity. The indicators of these titers reach different values depending on the stage of the tumor process, the presence of distant metastases, individual patient parameters, and the tumor response to the therapy. Given the high specificity of this biological marker, it is necessary to consider the possibility of its use as a prognostic indicator for assessing the success of the selected method of conservative treatment, as well as assessing the prognosis.Keywords
This publication has 15 references indexed in Scilit:
- The Clinical Utility of Plasma Epstein–Barr Virus DNA Assays in Nasopharyngeal CarcinomaMedicine, 2015
- Plasma Epstein–Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinomaAnnals of Oncology, 2014
- The role of plasma Epstein‐Barr virus DNA in the management of recurrent nasopharyngeal carcinomaThe Laryngoscope, 2013
- Role of plasma EBV DNA levels in predicting recurrence of nasopharyngeal carcinoma in a western populationBMC Cancer, 2012
- Plasma epstein‐barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinomaHead & Neck, 2011
- To build a prognostic score model containing indispensible tumour markers for metastatic nasopharyngeal carcinoma in an epidemic areaEuropean Journal of Cancer, 2011
- Salivary Epstein-Barr virus DNA level in patients with nasopharyngeal carcinoma following radiotherapyOral Oncology, 2011
- Different Clinical Significance of Pre- and Post-treatment Plasma Epstein–Barr Virus DNA Load in Nasopharyngeal Carcinoma Treated with RadiotherapyClinical Oncology, 2011
- Multiplexed immunobead‐based profiling of cytokine markers for detection of nasopharyngeal carcinoma and prognosis of patient survivalHead & Neck, 2010
- Plasma EBV DNA Clearance Rate as a Novel Prognostic Marker for Metastatic/Recurrent Nasopharyngeal CarcinomaClinical Cancer Research, 2010